Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-03-03
2003-12-16
Aulakh, C. S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S066000, C544S361000, C544S333000, C514S253030, C514S256000
Reexamination Certificate
active
06664263
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the general fields of pharmaceuticals and cancer chemotherapy, particularly to the areas of cytotoxic antitumor agents and DNA intercalating agents. The invention also relates to medicinal chemistry, and the fields of acridone and 1,8-naphthalimide organic chemistry.
BACKGROUND OF THE INVENTION
1. Acridine Intercalators
A number of acridine-based compounds which exhibit antitumor activity have been reported. Cholody et al. described 5-[(amino-alkyl)amino]-imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents (Cholody et al.,
J. Med. Chem
. 33:49-52 (1990)); 8-substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents (Cholody et al.,
J. Med. Chem
. 33:2852-2856 (1990)); and chromophore-modified imidazoacridones and their activity against murine leukemias (Cholody et al.,
J. Med. Chem
. 35:378-382 (1992)). Capps et al. described 2-(aminoalkyl)-5-nitropyrazolo[3,4,5-kl]acridines as a new class of anticancer agents (Capps et al.,
J. Med. Chem
. 35:4770-4778 (1992)). More recently, an 8-hydroxyimidazo[4,5,1-de]acridin-6-one, C1311, has entered clinical trials (Burger et al.,
Br. J. Cancer
74:1369-1374 (1996); Idem,
Br. J. Cancer
81:367-375 (1999)).
It is believed that DNA is the primary target for these compounds, and that they bind to DNA by intercalation. There is good evidence that intercalation of DNA by these drugs disrupts the activity of eukaryotic topoisomerase II (Capranico and Zunino,
Eur. J. Cancer
28A:2055-2060 (1992); Beck et al.,
Cancer Chemother. Pharmacol
. 34(Supp):S14-S18 (1994); Nitiss and Beck, Eur.
J. Cancer
32A:958-966 (1996)).
2. Naphthalimide Intercalators
Braña et al. have described naphthalimides with basic side chains which have anti-tumor activity (Braña et al.,
Cancer Chemother. Pharmacol
., 4:61-66 (1980);
Eur. J. Med. Chem
., 16:207-212 (1981); U.S. Pat. No. 4,204,063; U.S. Pat. No. 5,183,821). Examples which have reached the clinic include the compounds amonafide (Kornek et al.,
Eur. J. Cancer
, 30A:398-400 (1994)) and mitonafide (Rosell et al.,
Invest. New Drugs
, 10:171-175 (1992); Llombart et al., ibid., 177-181). Numerous other naphthalimide derivatives, among them nafidimide and azonafide, have been studied as well (Sami et al.,
J. Med. Chem
. 39:4978-4987 (1996) and references therein).
3. Acridine and Acridone Bis-intercalators
The strong binding to nucleic acids of bis-intercalators, which contain two planar aromatic systems joined by suitable linker, has long been known (Canellakis et al.,
Biochim. Biophys
. Acta 418:277-283 (1976)). Based upon the anti-tumor activity of the mono-intercalators, which were presumed to function by DNA intercalation, bis-intercalating compounds have been intensely studied as potential antitumor agents. It has been generally assumed that these compounds function by bis-intercalation of both chromophores into DNA.
Chen et al. studied diacridines as potential bifunctional intercalators (Chen et al,
J. Med. Chem
. 21:868-874 (1978)). Gaugain et al. described the synthesis and conformational properties of an ethidium homodimer and an acridine ethidium heterodimer (Gaugain et al.,
Biochemistry
17:5071-5078 (1978)). Sinha et al. described the synthesis and antitumor properties of bis(quinaldine) derivatives (Sinha et al.,
J. Med. Chem
. 20:1528-1531(1977)). Roques et al. described the antileukemic activity of pyridocarbazole dimers (Roques et al.,
Biochem. Pharmacol
. 28:1811-1815 (1979)). Wright et al. and Le Pecq et al. described bis-intercalating diacridines and the relationship of structure to DNA Binding (Wright et al.,
Biochemistry
, 19:5825-5836 (1990); Le Pecq et al.,
Eur. J. Biochem
., 180:359-366 (1989). Pelaprat et al. described 7H-pyridocarbazole dimers as potential antitumor agents (Pelaprat et al.,
J. Med. Chem
. 23:1336-1343 (1980)). Cholody et al., disclosed bis(imidazoacridone) derivatives active against colon tumor cells (Cholody et al.,
J. Med. Chem
. 38:3043-3052 (1995) and studied the mechanism of action (Hernandez et al.,
Cancer Res
. 55:2338-2345 (1995); see also Michejda et al., U.S. Pat. No. 5,508,289 and international application WO 97/38999, the entire disclosures of which are incorporated herein by reference. The same group of workers also disclosed certain bis(triazoloacridone) compounds active against HIV transcription (Turpin et al.,
Antimicrob. Agents Chemother
. 42:487-494 (1998).
4. Naphthalimide Bis-intercalators
Braña et al. have described bis-naphthalimides as a class of antitumor agents (Braña et al.,
Anti-Cancer Drug Design
8:257-268 (1993)). Kirshenbaum et al. described DMP-840, a bis-naphthalimide with promising antitumor activity (Kirshenbaum et al.
Cancer Res
. 54:2199-2206 (1994); and Nitiss et al. discussed the mechanism of action of DMP-840 (Nitiss et al.,
Biochemistry
37:3078-3085 (1998)).
Braña et al., in U.S. Pat. Nos. 4,874,863; 5,616,589; and 5,789,418 (all of which are incorporated herein by reference in their entirety), describe numerous bis(1,8-naphthalimide) compounds which have anti-tumor activity. Ardecky described similar acenaphthalene-derived bis-imide intercalators (Ardecky et al, U.S. Pat. No. 5,086,059), as did Cherney and Seitz in U.S. Pat. No. 5,359,070 (both of which are incorporated by reference herein). Cherney et al. have also described benzo- and hetero-fused bis(1,8-naphthalimide) derivatives which have anti-tumor activity (Cherney et al.,
Bioorg. Med. Chem. Letters
, 7:163-168 (1997); U.S. Pat. No. 5,585,382, incorporated by reference herein). Braña et al. have also disclosed benzo-fused 1,8-naphthalimides derived from anthracene1,9-dicarboxylic acid (Braña et al.,
J. Med. Chem
., 40:449-454 91997)). Sun et al. have described an extensive series of bis-naphthalimide antitumor agents (Sun et al., WO 92/17453; U.S. Pat. No. 5,206,249; U.S. Pat. No. 5,206,250; U.S. Pat. No. 5,376,664; U.S. Pat. No. 5,488,110; and U.S. Pat. No. 5,641,782, all of which are incorporated herein by reference in their entirety). Weis et al. described bis (1,8-naphthalimide anti-tumor agents having variations in the linker moiety (Weis et al., U.S. Pat. No. 5,604,095, incorporated herein by reference).
5. Structure-activity Relationships in DNA Intercalators
Many factors, such as physico-chemical characteristics of the planar chromophores, nature of the linking chain (length, rigidity, and ionization state), position of attachment, and other factors, strongly influence the binding with DNA and the biological action of these compounds. However, it has been found that although such compounds exhibit high affinity for DNA, there is little correlation between DNA binding affinity and cytotoxicity or antitumor activity. For example, some bis-intercalators are cytotoxic, while closely related compounds are merely cytostatic.
Since structure-activity relationships in the class of bis-intercalators in relation to their in vivo antitumor action remain unclear, it has not been possible to predict which structures will show such activity, even given their binding affinity for DNA. Small structural modifications can substantially alter the pharmacological properties of a DNA intercalator without similarly affecting DNA binding. Accordingly, research is still ongoing to find DNA intercalating compounds with high antineoplastic activity, especially those having selective activity towards specific tumors.
Compounds designed as potential bis-intercalating agents have typically consisted of two identical planar aromatic ring systems (“chromophores”) which are capable of intercalation between the base pairs of double-stranded DNA, joined by a flexible linker of suitable length. Compounds having two identical chromophores are referred to herein as “symmetrical”. Previous workers in the field have generally assumed that the mechanism of action of bifunctional intercalators depends upon intercalation of both chromophores into DNA (hence the generic term “bis-intercalator”). B
Cholody Wieslaw M.
Kosakowska-Cholody Teresa
Michejda Christopher J.
Aulakh C. S.
Corless Peter F.
Edwards & Angell LLP
O' Day Christine C.
The United States of America as represented by the Department of
LandOfFree
1,8-naphthalimide imidazo{4,5,1-de}acridones with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,8-naphthalimide imidazo{4,5,1-de}acridones with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,8-naphthalimide imidazo{4,5,1-de}acridones with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3140578